Life-years gained from defibrillator implantation - Markedly nonlinear increase during 3 years of follow-up and its implications

被引:53
作者
Salukhe, TV
Dimopoulos, K
Sutton, R
Coats, AJ
Piepoli, M
Francis, DP
机构
[1] Royal Brompton Hosp, Pacing & ICD Dept, London SW3 6NP, England
[2] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England
[3] Univ Sydney, Fac Med, Sydney, NSW 2006, Australia
[4] St Marys Hosp, Cardiac Performance Unit, London, England
[5] St Marys Hosp, Dept Cardiol, London, England
关键词
survival; defibrillator; follow-up studies;
D O I
10.1161/01.CIR.0000125522.10053.29
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background - Although treatment benefit in randomized controlled trials of defibrillators is often summarized by the numbers of lives saved ( absolute risk difference), this may not be a good representation of what matters most to patients, namely, the amount of life they should expect to gain from implantation. The estimate of gain in life-years may depend on duration of follow-up. In this study, we examine this dependency. Methods and Results - We estimated, from published data of 8 landmark defibrillator trials, the cumulative benefit in life-years gained at time points from 3 months to 3 years. Because the trial populations, clinical status, and prognosis varied widely between studies, we expressed for each study the benefit at each time point as the proportion of benefit at 3 years. The average dependency of the benefit on duration of follow-up was then calculated. We found that the number of life-years gained from 1 device implantation increases with length of follow-up considered. Importantly, this increase is markedly nonlinear. Within the 3-year span addressable, the benefit rises with the square of time (gain proportional to t(1.94), R-2 = 0.998, P < 0.001). Conclusions - Measurable benefit from a defibrillator to patients' life spans (life-years gained) is dramatically dependent on the time window over which the benefit is assessed. Because the effort of implantation is front loaded, yet benefit grows with time, the choice of an early time point artificially reduces apparent benefit and artificially increases the apparent number needed to treat to prevent an event. These are useful considerations for the formulation of treatment policy ( and even for planning of the follow-up phase of clinical trials).
引用
收藏
页码:1848 / 1853
页数:6
相关论文
共 11 条
[1]  
BAROL HS, 2002, CLIN STAT SUMMARY ME
[2]   A randomized study of the prevention of sudden death in patients with coronary artery disease [J].
Buxton, AE ;
Lee, KL ;
Fisher, JD ;
Josephson, ME ;
Prystowsky, EN ;
Hafley, G .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (25) :1882-1890
[3]   Canadian implantable defibrillator study (CIDS) - A randomized trial of the implantable cardioverter defibrillator against amiodarone [J].
Connolly, SJ ;
Gent, M ;
Roberts, RS ;
Dorian, P ;
Roy, D ;
Sheldon, RS ;
Mitchell, LB ;
Green, MS ;
Klein, GJ ;
O'Brien, B .
CIRCULATION, 2000, 101 (11) :1297-1302
[4]  
*GUID CORP, 2001, CONTAK CD EASY TRAK, P11
[5]   Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest -: The Cardiac Arrest Study Hamburg (CASH) [J].
Kuck, KH ;
Cappato, R ;
Siebels, J ;
Rüppel, R .
CIRCULATION, 2000, 102 (07) :748-754
[6]  
McAnulty J, 1997, NEW ENGL J MED, V337, P1576
[7]   Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia [J].
Moss, AJ ;
Hall, WJ ;
Cannom, DS ;
Daubert, JP ;
Higgins, SL ;
Klein, H ;
Levine, JH ;
Saksena, S ;
Waldo, AL ;
Wilber, D ;
Brown, MW ;
Heo, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (26) :1933-1940
[8]   Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction [J].
Moss, AJ ;
Zareba, W ;
Hall, WJ ;
Klein, H ;
Wilber, DJ ;
Cannom, DS ;
Daubert, JP ;
Higgins, SL ;
Brown, MW ;
Andrews, ML .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (12) :877-883
[9]   Comparison of medical therapy, pacing and defibrillation in heart failure (COMPANION) trial terminated early; combined biventricular pacemaker-defibrillators reduce all-cause mortality and hospitalization [J].
Salukhe, TV ;
Francis, DP ;
Sutton, R .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2003, 87 (2-3) :119-120
[10]   Electrophysiologically guided amiodarone therapy versus the implantable cardioverter-defibrillator for sustained ventricular tachyarrhythmias after myocardial infarction -: Results of long-term follow-up [J].
Schläpfer, J ;
Rapp, F ;
Kappenberger, L ;
Fromer, M .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (11) :1813-1819